Floatz logo

Golidocitinib

Lung Cancer, Non-Small Cell

Peking University Cancer Hospital & InstituteSmall moleculePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Lung Cancer, Non-Small Cell cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Golidocitinib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
63 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
mature T-cell and NK-cell non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →